Call for Abstracts
Call for Abstracts Now Closed
The Program Committee thanks you for your scientific abstract submissions for the IASLC 2023 World Conference on Lung Cancer. The notification of abstract acceptance will be sent out on May 31, 2023 (11:59 SGT).
|Abstract Submission Opens||January 26, 2023 (11:59 SGT)|
|Abstract Submission Deadline||April 14, 2023 (23:59 PST) / April 15, 2023 (15:59 SGT)|
|Education Awards Application Deadline||April 14, 2023 (23:59 PST) / April 15, 2023 (15:59 SGT)|
|Notification of Abstract Acceptance||May 31, 2023 (11:59 SGT)|
|Notification of Education Awards||May 31, 2023 (11:59 SGT)|
|Late-Breaking Abstract Deadline||June 16, 2023 (23:59 PST) / June 17, 2023 (15:59 SGT)|
|Late-Breaking Abstract Notifications||July 12, 2023 (11:59 SGT)|
|Presenting Author Registration Deadline||July 14, 2023 (11:59 SGT)|
|Abstract Title Release||July 25, 2023|
|Full Abstract Release Date|
(Except for Embargoed Abstracts)
|August 16, 2023 (07:00 PDT/22:00 SGT)|
- Risk Factors, Risk Reduction & Tobacco Control
This would include classic epidemiology, family history, gender differences, lung cancer in never smokers, exposure to radon, tobacco, and asbestos, cessation programs, chemoprevention, efforts to reduce tobacco production, sales, and distribution.
- Tumor Biology – Preclinical Biology
This would include in vitro basic science studies and mouse cell lines.
- Tumor Biology – Translational Biology
This would include patient derived cells, animal models, and drug development studies.
- Screening and Early Detection
This would include LDCT and radiology but also ongoing research into other methods and technologies to screen and detect thoracic cancers early.
- Pulmonology and Staging
This would include EUS, EBUS, NB, PET-CT, mediastinoscopy, and staging system analyses.
- Pathology and Biomarkers
This would include anatomic and molecular pathology, tissue and circulating biomarker studies, clinical trial associated predictive biomarkers.
- Early-Stage Non-small Cell Lung Cancer
This would include clinically related studies on localized/early-stage NSCLC, surgery, radiation therapy, neoadjuvant and adjuvant therapies, and immunotherapy and targeted therapies in this setting.
- Local-Regional Non-small Cell Lung Cancer
This would include clinically related studies on loco-regional/locally advanced NSCLC (Stage III), surgery, radiation therapy, neoadjuvant and adjuvant therapies, immunotherapy and targeted therapies in this setting, and new multi-modality approaches.
- Metastatic Non-small Cell Lung Cancer – Local Therapies
This would include radiation therapy, surgery, and other ablative techniques.
- Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy
This would include clinically relevant studies in metastatic advanced NSCLC related to targeted therapy, including chemotherapy and nonclassical chemotherapy agents (ie ADCs), radiation oncology, new agents, new combinations, and new sequencing of drugs.
- Metastatic Non-small Cell Lung Cancer – Immunotherapy
This would include clinically relevant studies in metastatic advanced NSCLC related to immunotherapy, including new agents, new combinations including radiation oncology, and new sequencing of drugs.
- Metastatic Non-small Cell Lung Cancer – Targeted Therapy
This would include clinically relevant studies in metastatic advanced NSCLC related to targeted therapy, including new agents, new combinations including radiation oncology, and new sequencing of drugs.
- Small Cell Lung Cancer and Neuroendocrine Tumors
This would include clinically related studies on small cell lung cancer and neuroendocrine tumors. Strictly translational and basic science studies should go to tumor biology.
- Mesothelioma, Thymoma, and Other Thoracic Tumors
This would include clinically related studies on mesothelioma, thymoma, thymic carcinoma, esophageal cancer.
- Multidisciplinary Care: Nursing, Allied Health and Palliative Care
This would include nursing, allied health, palliative and supportive care, symptom management, decision-making, decision support techniques, ethics, quality of life, integrative care, rehabilitation, physiotherapy, survivorship care.
- Patient Advocacy
This would include patient advocacy, patient survivorship, community outreach, patient-driven research, advocacy and patient foundations and organizations, patient reported outcomes, lung cancer stigma.
- Global Health, Health Services, and Health Economics
This would include large real-world database studies across tumor types and stages, disparities identification and solutions, studies that examine cost-effectiveness of therapies, diagnostics, or pathway implementation, programs that help improve efficiency of health systems or patient management, and registry creation descriptions.
Definition: Original scientific research that summarizes work done and major research findings.
Required sections for abstract submission:
Clinical Trials in Progress (eligible for designation as e-poster only)
Definition: Ongoing trials that have not reached pre-specified endpoints for analysis.
Case Report (eligible for designation as e-poster only)
Definition: Detailed report of symptoms, signs, diagnosis, treatment and follow up of an individual patient.
Required sections for abstract submission:
Late-Breaking Abstract (LBA) Submission
Definition: LBA designation will only be given to prospective randomized studies or original research that have practice changing potential for which data is not available at the time of abstract placeholder submission due to study timelines.
LBA designation is not a means for extending the regular abstract deadline. Any abstract that fails to meet LBA requirements will be designated as a regular abstract and rated based on the information available on the submission deadline.
Submission requirements: Authors of LBA must submit a place holder abstract through the abstract portal by April 14, 2023 (23:59 PST).
Required sections for place holder abstracts:
- Explanation of why the abstract qualifies as late-breaking (including the endpoints for which data will be provided and the date for which the abstract will be updated prior to the LBA final submission deadline on June 16, 2023).
- Methods, including endpoints measured
- Types of analysis and anticipated data reporting
- Results and conclusion will be submitted by June 16, 2023
Review: The Scientific Program Committee will review LBA abstract placeholder applications. Authors of approved LBAs will be notified and instructed on deadlines and the processes for submitting final data by June 16, 2023, the final LBA deadline. LBA abstracts not completed by the June 16, 2023 deadline will be automatically withdrawn and will not be considered for the meeting.
To foster high-quality oral and written presentations at IASLC conferences, an implementation team will conduct a review of abstract titles and provide suggestions based on the IASLC Language Guide. We encourage you to review the Guide prior to submitting your abstract, to minimize later suggestions or edits and to help facilitate mutually respectful communication.
Word Limit: 500 words (does not include title and authors)
Abstracts should be organized in different sections based on the selected abstract type. Please refer to the 'Abstract Type' section on this page for further information.
Title Word Limit: 125 characters total (including spaces).
Tables: No limit; each table counts as 100 words.
Images: 2 maximum; each image counts as 100 words.
Format(s): Upload tables, images and graphs in GIF, JPEG, JPG or PNG format of a minimum of 300 dpi and 100% size. Higher resolution is acceptable and preferred.
Fee: No submission fee
Submission Limit: Presenters are limited to 2 oral presentations.
Number of Co-authors: No limit
Encore Submission: An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the abstract. Submitters are required to list any previously presented abstracts in the introduction of the abstract.
Financial disclosure and affiliation information is required for the presenting author. For reference, here is a link to the disclosure form.
Publication: Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the conference website. Most abstracts will be published and released prior to the meeting, except for embargoed abstracts which will be posted on the day of presentation.
These awards are presented to individuals with high scoring abstracts who meet categorical eligibility criteria and who apply. Applications must be completed by the abstract and education award submission deadline April 14, 2023 (23:59 PST).
Definition: Plagiarism encompasses all of following:
- Direct: intentionally submitting another person’s words or ideas verbatim as one’s own;
- Self-plagiarism: submitting work that has been previously published or presented;
- Mosaic plagiarism: stringing together portions of text from other sources; and
- Lack of attribution: failing to appropriately identify and cite sources for language or ideas that are incorporated.
For more information see: Das N, Panjabi M. Plagiarism: Why is it such a big issue for medical writers? Perspect Clin Res. 2011;2(2):67–71. doi:10.4103/2229-3485.80370
- Screening: IASLC screens all abstracts using anti-plagiarism software. Abstracts identified as having high levels of plagiarized content will be evaluated by IASLC staff and appropriate actions taken.
- Penalties for plagiarism may include: Rejection of abstract, and/or author(s) banned from making presentations at IASLC conferences.
Independence of Educational Activities Policy
- Employees of ACCME defined ineligible companies are prohibited from presenting educational content for Continuing Medical Education. Consequently, employees of ineligible companies are prohibited from giving presentations during accredited CME sessions (e.g., Presidential and plenary symposia, invited educational sessions) .
- In situations where the presenting author is an employee of an ineligible company, the abstract will automatically be considered for an e-poster.
- Presenting authors must be registered for WCLC 2023 independent of an ineligible company, except for employees of ineligible companies, who are allowed to be registered by their employers.
- Presenting author must control all content. Ineligible companies may not influence scientific content by requiring the use of company slide decks or other materials. Scientific data generated by industry sponsored research is permissible.
- Content of educational activities must be well-balanced, evidence based and unbiased. Generic names should be used to the extent possible.
- Ineligible companies/commercial interests may not submit registration materials or fees on behalf of learners, faculty or others attendee types.
When will the abstract titles be published online?
Abstract titles will be released July 25, 2023.
When will the full abstracts be published online?
The full abstract bodies will be released on August 16, 2023, except those abstracts included in the WCLC 2023 Press Program.
Does WCLC accept abstracts that have been submitted and presented to a previous Conference (ie, encore abstracts, trials in progress encore abstracts)?
An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the presentation. Submitters are required to list any previous presentations during the abstract submission process.
Are case reports/case series considered for presentations?
Yes, we do allow the submission of case reports.
What is the withdrawal deadline for regular submissions and late breaking submissions?
The presenting author registration deadline is July 14, 2023. Abstract presentations for a presenter not registered by this date will be withdrawn from the program.
For late-breaking abstracts, does the Conference only permit abstracts that report on Phase 3 [and higher] studies?
Only clinically relevant prospective studies in which data is not available at the time of abstract placeholder submission (April 14, 2023) due to study timelines will be granted late-breaking submission privileges. An abstract study does not need to be a Phase III clinical trial to be eligible for late-breaking data submission.
Could I send my manuscript to publish to a journal in my country before WCLC?
Submitters may submit their abstract to be published in a journal prior to the abstract being released in conjunction with WCLC, however, the Scientific Program Committee will be reviewing abstracts for novelty and impact on patient care, and a publication in a journal prior to the meeting may impact the scoring of the abstract.
Is industry allowed to be in lead or senior author positions on the author list for WCLC abstract submissions? Are there restrictions towards pharmaceutical/commercial authors on presenting abstracts at the meeting?
Yes, industry is permitted to be in the lead and senior author positions in the author list of an abstract. Industry/pharmaceutical/commercial authors are prohibited from presenting Presidential, Oral, and Mini Oral presentations. Industry/pharmaceutical/commercial authors are permitted to present e-poster presentations.
Would it be possible to submit an abstract without results and conclusion?
All Regular Abstracts, Clinical Trials in Progress Abstracts, and Case Report abstracts must be completed by the April 14, 2023 deadline. Any Regular Abstracts and Case Reports that are incomplete after the April 14, 2023 deadline will be automatically withdrawn and will not be considered for the meeting. Clinical Trials in Progress abstracts may be submitted and completed by the April 14, 2023 deadline without Results and Conclusions as those sections are optional for CTPS submissions. Late-breaking Abstract designation will only be given to clinically relevant prospective studies in which data is not available at the time of abstract placeholder (April 14, 2023) due to study timelines. To submit a late-breaking abstract, you must submit a placeholder abstract including all components of the abstract except for the Results and Conclusions by the April 14, 2023 deadline.
Is there a limit on the number of abstracts in which an author can be lead author?
There is no limit to the number of abstracts in which an author can be lead author. An individual may not give more than two oral presentations.
Is there any charge for the submission of abstracts, and if so, how much is it?
No, there is no charge to submit an abstract to WCLC.
For inquiries, please contact [email protected].
If your inquiry is regarding a particular draft or submission, please include the abstract ID in your email.